精神分裂症患者使用长效注射剂与口服抗精神病药的全因死亡风险:系统综述与Meta分析
该系统综述与Meta分析纳入17篇文章、共12042例患者(口服5795例,长效注射剂6247例),比较长效注射剂与口服抗精神病药的全因、自杀及非自杀死亡风险。长效注射剂组全因死亡风险低于口服组(OR=0.79;95%CI=0.66-0.95),非自杀死亡风险亦较低(OR=0.77;95%CI=0.63-0.94;p=0.01),自杀死亡无显著差异(OR=0.86;95%CI=0.59-1.26;p=0.44)。作者认为应尽可能从首发精神病阶段考虑使用长效注射剂。
要点
- 长效注射剂组全因死亡风险低于口服组(OR=0.79;95%CI=0.66-0.95)。
- 非自杀死亡风险较低(OR=0.77;95%CI=0.63-0.94;p=0.01),自杀死亡无显著差异(OR=0.86;95%CI=0.59-1.26;p=0.44)。
- 作者认为应尽可能从首发精神病阶段考虑使用长效注射剂。
核心结论
- 长效注射剂抗精神病药与精神分裂症患者较低的全因和非自杀死亡风险相关。
- 作者认为应尽可能从首发精神病阶段考虑使用长效注射剂。
研究设计与样本
- 随机效应Meta分析(PROSPERO:CRD42023391352),纳入17篇文章、总样本12042例患者(口服5795例,长效注射剂6247例)。
- 分别分析单个及汇总长效注射剂与汇总口服抗精神病药的比较,并按研究设计、设置和产业赞助进行敏感性分析,按性别、年龄、抗精神病药剂量和种族进行Meta回归。
主要发现
- 长效注射剂组较口服组全因死亡风险降低(OR=0.79;95%CI=0.66-0.95)。
- 仅纳入同一长效注射剂与口服抗精神病药比较的研究时,全因死亡风险降低仍具统计学显著性(OR=0.79;95%CI=0.66-0.95;p=<0.01)。
- 非自杀死亡风险降低(OR=0.77;95%CI=0.63-0.94;p=0.01),自杀死亡风险无显著差异(OR=0.86;95%CI=0.59-1.26;p=0.44)。
- 首发精神病患者中长效注射剂的全因死亡风险降低较慢性精神病更明显(OR=0.79;95%CI=0.66-0.96)。
- 无单个长效注射剂与汇总口服抗精神病药比较报告统计学显著差异。
关键数值与推荐
- 全因死亡:长效注射剂组 vs 口服组 OR=0.79(95%CI=0.66-0.95)。
- 非自杀死亡:长效注射剂组 vs 口服组 OR=0.77(95%CI=0.63-0.94;p=0.01)。
- 自杀死亡:长效注射剂组 vs 口服组 OR=0.86(95%CI=0.59-1.26;p=0.44)。
- 首发精神病:长效注射剂组 vs 口服组 OR=0.79(95%CI=0.66-0.96)。
临床怎么用
- 作者认为应尽可能从首发精神病阶段考虑使用长效注射剂。
- 作者认为更好的药物依从性和健康服务可解释长效注射剂与口服抗精神病药之间的死亡风险差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with schizophrenia receiving antipsychotic treatment present lower mortality rates than those who do not. However, the non-adherence rate is high, which can be partially addressed using long-acting injectable (LAI) antipsychotics. The impact of LAI treatments on all-cause mortality compared to oral antipsychotics remains unclear. To fill that gap, a random effects meta-analysis was conducted to analyze the odds ratio (OR) of all-cause, suicidal, and non-suicidal mortality among patients taking LAI antipsychotics compared to oral antipsychotics (PROSPERO:CRD42023391352). Individual and pooled LAI antipsychotics were analyzed against pooled oral antipsychotics. Sensitivity analyses were performed for study design, setting, and industry sponsorship. Meta-regressions were conducted for gender, age, antipsychotic dose, and race. Seventeen articles, total sample 12,042 patients (N = 5795 oral, N = 6247 LAI) were included. Lower risk of all-cause mortality for patients receiving LAI antipsychotics vs receiving oral antipsychotics was found (OR = 0.79; 95%CI = 0.66-0.95). Statistical significance was maintained when only studies comparing the same LAI and oral antipsychotic were included (OR = 0.79; 95%CI = 0.66-0.95; p = <0.01), as well as for non-suicidal mortality (OR = 0.77: 95%CI = 0.63-0.94; p = 0.01), but not for suicidal mortality (OR = 0.86; 95%CI = 0.59-1.26; p = 0.44). Mortality reduction was more pronounced for LAI antipsychotics in first-episode psychosis (FEP) (OR = 0.79; 95%CI = 0.66-0.96) compared to chronic psychosis. No individual LAI reported statistically significant differences against all pooled oral antipsychotics. LAI antipsychotics are associated with a lower risk of all-cause and non-suicidal mortality in individuals with schizophrenia compared to oral antipsychotics. Better adherence to the medication and health services may explain this difference. Whenever possible, the use of LAIs should be considered from the FEP.
引用
- Aymerich C, Salazar de Pablo G, Pacho M, et al. All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis. Mol Psychiatry. 2024. PMID: 39174648. doi:10.1038/s41380-024-02694-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。